December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

BioNTech SE - American Depositary Shares (NQ:BNTX)

90.17 +3.25 (+3.74%)
Delayed Quote Updated: 12:28 PM EST, Nov 4, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about BioNTech SE - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
News headline image
BioNTech Announces Third Quarter 2026 Financial Results and Corporate Update
From BioNTech SE
Via GlobeNewswire
News headline image
A Personalized Cancer Therapy Delivered Positive Phase 3 Results; The Next Race Is Picking Better Targets
News Provided by Biotech Insider on behalf of MindWalk Holdings Corp. 
From Biotech Insider
Via GlobeNewswire
News headline image
BioNTech and DualityBio Announce Topline Results of the DYNASTY-Breast02 Global Phase 3 Clinical Trial Evaluating Trastuzumab Pamirtecan in HR+/HER2-low Metastatic Breast Cancer
From BioNTech SE
Via GlobeNewswire
News headline image
BioNTech and Bristol Myers Squibb Report Encouraging Global Phase 2 Data for Pumitamig in Advanced NSCLC After Progression on Immunotherapy Plus Chemotherapy
From BioNTech SE
Via GlobeNewswire
News headline image
BioNTech Advances Phase 3 Clinical Trial of Pumitamig in Combination with Gilead’s TROP2-Directed ADC Sacituzumab Govitecan in Triple-Negative Breast Cancer
From BioNTech SE
Via GlobeNewswire
News headline image
BioNTech to Report Third Quarter 2026 Financial Results and Corporate Update on November 3, 2026
From BioNTech SE
Via GlobeNewswire
News headline image
BioNTech to Showcase Oncology Late-Stage Pipeline Progress and Pumitamig Novel-Novel Combination Data at ESMO 2026
From BioNTech SE
Via GlobeNewswire
News headline image
BioNTech Provides Update on Phase 2/3 Clinical Trial for mRNA Cancer Immunotherapy Candidate BNT113 in Metastatic HPV16-positive Head and Neck Cancer
From BioNTech SE
Via GlobeNewswire
News headline image
A $57 Billion Antiviral Market Is Taking Shape As The World Prepares For The Next Viral Threat
EQNX::TICKER_START (NYSE:NNVC),(NASDAQ:GILD),(NASDAQ:MRNA),(NYSE:PFE),(NASDAQ:BNTX) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
A $57 Billion Antiviral Market Is Taking Shape As The World Prepares For The Next Viral Threat
A Growing Global Threat From Emerging Viruses Is Fueling Urgent Demand For New Treatments And Creating A Potentially Massive Market For Innovative Antiviral Developers 
From MarketNewsUpdates.com
Via GlobeNewswire
News headline image
BioNTech and OncoC4 Present Updated Data Showing Gotistobart Nearly Doubled Median Overall Survival versus Standard-of-Care Chemotherapy in Previously Treated Squamous Non-Small Cell Lung Cancer Patients
From BioNTech SE
Via GlobeNewswire
News headline image
Pfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 Vaccine
From Pfizer Inc.
Via Business Wire
News headline image
Pfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 Vaccine
From BioNTech SE
Via GlobeNewswire
News headline image
A Multibillion-Dollar mRNA Cancer Market Is Taking Shape Targeting Lung Cancer’s Biggest Opportunity
EQNX::TICKER_START (NASDAQ:SBFM),(NASDAQ:BNTX),(NYSE:AZN),(NASDAQ:MRNA),(NYSE:BMY) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
A Multibillion-Dollar mRNA Cancer Market Is Taking Shape Targeting Lung Cancer’s Biggest Opportunity
A New Generation of Personalized Cancer Treatments Could Open a Multibillion-Dollar Market for Precision Oncology 
From MarketNewsUpdates.com
Via GlobeNewswire
News headline image
BioNTech Highlights Late-Stage Lung Cancer Pipeline Momentum and First Global Data for Pumitamig/Elfetabart Drozuntecan Novel-Novel Combination at WCLC 2026
From BioNTech SE
Via GlobeNewswire
News headline image
BioNTech Announces Second Quarter 2026 Financial Results and Corporate Update
From BioNTech SE
Via GlobeNewswire
News headline image
BioNTech Announces Appointment of Guido Oelkers to Management Board as Chief Executive Officer
From BioNTech SE
Via GlobeNewswire
News headline image
European Commission Authorizes Pfizer and BioNTech XFG-adapted COVID-19 Vaccine in the European Union
From Pfizer Inc.
Via Business Wire
News headline image
European Commission Authorizes Pfizer and BioNTech XFG-adapted COVID-19 Vaccine in the European Union
From BioNTech SE
Via GlobeNewswire
News headline image
BioNTech to Report Second Quarter 2026 Financial Results and Corporate Update on August 4, 2026
From BioNTech SE
Via GlobeNewswire
News headline image
Global Data for BioNTech and Bristol Myers Squibb’s PD-L1xVEGF-A Bispecific Pumitamig Shows Encouraging Efficacy in Patients with Non-Small Cell Lung Cancer in ROSETTA Lung-02 Trial
From BioNTech SE
Via GlobeNewswire
News headline image
BioNTech to Showcase Progress Across Late-Stage Oncology Pipeline at the 2026 ASCO Annual Meeting
From BioNTech SE
Via GlobeNewswire
News headline image
BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2026
From BioNTech SE
Via GlobeNewswire
News headline image
BioNTech Announces New ADS Repurchase Program
From BioNTech SE
Via GlobeNewswire
News headline image
BioNTech Announces First Quarter 2026 Financial Results and Corporate Update
From BioNTech SE
Via GlobeNewswire
News headline image
BioNTech to Report First Quarter 2026 Financial Results and Corporate Update on May 5, 2026
From BioNTech SE
Via GlobeNewswire
News headline image
BioNTech and DualityBio’s Antibody-Drug Conjugate Trastuzumab Pamirtecan Demonstrated Clinically Meaningful Efficacy in Patients with HER2-Expressing, Recurrent Endometrial Cancer
From BioNTech SE
Via GlobeNewswire
News headline image
BioNTech Clinical Data at ELCC 2026 Highlight Potential of Differentiated Late-Stage Portfolio in Lung Cancer
From BioNTech SE
Via GlobeNewswire
News headline image
BioNTech Announces Fourth Quarter and Full Year 2025 Financial Results and Corporate Update
From BioNTech SE
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.